Alzheimer's disease (AD) and Type 2 Diabetes Mellitus (T2DM) are two of the most
prevalent diseases in the elderly population worldwide. A growing body of epidemiological …

Neuroinflammatory processes are a central feature of Alzheimer's disease (AD) in which
microglia are over-activated, resulting in the increased production of pro-inflammatory …

Alzheimer's disease (AD) affects nearly 50 million people worldwide, and currently no
disease-modifying treatment is available. With continuous failure of anti-amyloid-beta-or tau …

Chronic glial activation and neuroinflammation induced by the amyloid‐β peptide (Aβ)
contribute to Alzheimer's disease (AD) pathology. APOE 4 is the greatest AD‐genetic risk …

Alzheimer's disease (AD) is marked by the presence of amyloid beta (Aβ) plaques,
neurofibrillary tangles (NFT), neuronal death and synaptic loss, and inflammation in the …

Alzheimer's disease is the leading cause of dementia. Its increased prevalence in
developed countries, due to the sharp rise in ageing populations, presents one of the …

Involvement of life stress in Late-Onset Alzheimer's Disease (LOAD) has been evinced in
longitudinal cohort epidemiological studies, and endocrinologic evidence suggests …

Alzheimer's disease (AD) is the most common neurodegenerative disease and the most
common cause of dementia. Among various pathophysiological aspects, microglia are …

Alzheimer's disease (AD) is the leading cause of dementia in older adults. It is more than 50
years since vitamin E was recognized as critical for optimal neurological health. Clinical …

Alzheimer's disease (AD) is a complex genetic disorder. To date, published data have
reported conflicting results on the role of CD33 rs3865444 polymorphism in AD. The present …